Related Experiment Video
Updated: Sep 4, 2025
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Rohan R Katipally1, Sean P Pitroda1, Aditya Juloori1
1Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, IL, USA.
Abstract:
Metastases remain the leading cause of cancer-related mortality. The oligometastasis hypothesis postulates that a spectrum of metastatic spread exists and that some patients with a limited burden of metastases can be cured with ablative therapy. Over the past decade, substantial advances in systemic therapies have resulted in considerable improvements in the outcomes of patients with metastatic cancers, warranting re-examination of the oligometastatic paradigm and the role of local ablative therapies within the context of the improved therapeutic responses, shifting patterns of disease recurrence and possible synergy with systemic treatments. Herein, we reframe the oligometastatic phenotype as a dynamic state for which locally ablative, metastasis-directed therapy improves clinical outcomes, including by prolonging survival and increasing cure rates. Important risk factors defining the metastatic spectrum are highlighted that inform both staging and therapy. Finally, we synthesize the literature on combining local therapies with modern systemic treatments, identifying general themes to optimally integrate ablative therapies in this context.
Insights
Metastasis is a major cause of cancer death. This study reframes oligometastasis as a dynamic state where local ablative therapy can improve survival and cure rates for limited metastatic burden.
Area of Science:
- Oncology
- Cancer Metastasis Research
Background:
- Metastases are the primary cause of cancer mortality.
- The oligometastasis hypothesis suggests limited metastatic disease may be curable with ablative therapy.
Purpose of the Study:
- To re-examine the oligometastatic paradigm in light of advances in systemic therapies.
- To explore the role of local ablative therapies in conjunction with modern systemic treatments.
- To reframe the oligometastatic phenotype as a dynamic state.
Main Methods:
- Literature synthesis on combining local therapies with systemic treatments.
- Identification of risk factors defining the metastatic spectrum.
- Analysis of shifting patterns of disease recurrence and therapeutic synergy.
Main Results:
- Locally ablative, metastasis-directed therapy can improve clinical outcomes in the oligometastatic phenotype.
- This approach may prolong survival and increase cure rates.
- Risk factors are identified to inform staging and therapy.
Conclusions:
- The oligometastatic phenotype is a dynamic state.
- Integrating local ablative therapies with modern systemic treatments can optimize patient outcomes.
- Further research is needed to refine the optimal integration of these therapies.
